FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to cardiology, and concerns treatment of patients with hypertrophic cardiomyopathy. That is ensured by genotype determination, and genotype AA ATR1 requires introduction of irbesartan in dosage 75-300 mg once a day.
EFFECT: higher clinical effectiveness in the case patients.
1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING PATIENT WITH HYPERTROPHIC CARDIOMYOPATHY | 2013 |
|
RU2540475C1 |
| METHOD FOR PREDICTION OF UNFAVOURABLE OUTCOME OF HYPERTROPHIC CARDIOMYOPATHY | 2013 |
|
RU2527768C1 |
| METHOD FOR PREDICTING ENALAPRYL EFFICIENCY IN TREATING HYPERTENSION DISEASE PATIENTS IN RUSSIAN PEOPLE POPULATION | 2006 |
|
RU2305837C1 |
| METHOD FOR DETERMINING OF RISK OF CARDIO-VASCULAR COMPLICATIONS DEVELOPMENT IN PATIENTS WITH HYPERTENSION | 2006 |
|
RU2334466C2 |
| METHOD FOR LEFT VENTRICULAR HYPERTROPHY CORRECTION IN ELDERLY AND SENILE PATIENTS WITH ARTERIAL HYPERTENSION | 2014 |
|
RU2568902C2 |
| DIAGNOSTIC TECHNIQUE FOR DEVELOPING PAINLESS MYOCARDIAL ISCHEMIA IN YOUNG FEMALES WITH ESTROGEN DEFICIENCY WITH ARTERIAL HYPERTENSION IN LATE FERTILE PERIOD DEPENDING ON INTERGENIC INTERACTIONS | 2015 |
|
RU2601381C1 |
| METHOD OF DRUG TREATMENT OF PATIENTS IN LATE REHABILITATION PERIOD AFTER AORTOCORONARY BYPASS SURGERY | 2013 |
|
RU2545985C2 |
| METHOD FOR OPTIMISATION OF MEN CARDIOTROPIC THERAPY AND HORMONE REPLACEMENT THERAPY IN CASE OF ANDROGENODEFICIENCY WITH ARTERIAL HYPERTENSION | 2016 |
|
RU2632449C1 |
| DIAGNOSTIC TECHNIQUE FOR LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2009 |
|
RU2429785C2 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF VARIOUS DEGREES OF SEVERITY OF CHRONIC HEART FAILURE | 2021 |
|
RU2772359C1 |
